The promise of Tele-Dementia: Today’s science and tomorrow’s trial

Telemedicine is the term used to describe the use of technology to provide medical care over a distance. Telephone, email, and real-time videoconferencing are the most frequently used telepsychiatry technology. Telemedicine has been used to provide simple and efficient healthcare solutions in the treatment of illness. Despite it is relatively new, mobile health (mHealth) has grown significantly in popularity as a means of assisting persons living with a chronic condition. The current study reviewed existing mobile health dementia applications from different perspectives. These applications could include a variety of strategies and resources to assist the community especially in caring for individuals with Alzheimer's disease

Atypical antipsychotic Lumateperone beyond Schizophrenia: seeking clarity in a time of uncertainty

Lumateperone (ITI-007) is a serotonin 5HT2A tosylate salt with high affinity for dopamineD2 and D1 receptors and the serotonin transporter. It is unusual in that it controlsserotonin, dopamine, and glutamate neurotransmission concurrently, all of which havebeen implicated in severe mental illness. Consider it a multi-targeted ligand andmultifunctional modulator of the serotoninergic system with possible precognitive,antipsychotic, antidepressant, and anxiolytic properties. While lumateperone has beenexplored as a new agent for schizophrenia therapy, it also provides a unique therapeuticoption for a range of other psychiatric and neurological diseases, including behaviouralsigns of dementia or Alzheimer's disease, sleep problems, and bipolar depression.Additionally, it had a better safety profile than placebo, with no significant extrapyramidalside effects, hyperprolactinemia, or changes in cardiometabolic or endocrinecharacteristics. Additional study is needed to validate and analyse lumateperone's1 effectiveness, as well as to identify prospective therapeutic targets. This article gives acomprehensive overview of the most notable results and potential future applications ofthis chemical in personalised medicine, particularly for neurodegenerative disease

A case study of multiple sclerosis (MS)

This is a CASE STUDY OF MULTIPLE SCLEROSIS (MS) is designed to be a PBL for teaching for Medical students

Arab-Muslims contributions to modern neuroscience: what’s giving us hope?

The Arab world encompasses a broader geographical area, covering a wide variety of countries in Asia and Africa.Arab culture is due to much of its development in all the fields of intellectual practice, including in medicine, particularly during the Golden Age of the Arabic Islamic sciences (8th –13th centuries C.E.). The glorious history of the Arab world allows us to consider the debt of mankind to the golden age of Arab science and assess the contribution of Arab countries to our day's biomedicaland neuroscienceresearch

Parkinson’s genetics research on underrepresented AfrAbia populations: current state and future prospects

Parkinson’s disease (PD), the most common motoric neurodegenerative illness, has been extensively researched to better understand its complex pathophysiology. Nearly 80% of genome-wide association studies have been conducted on persons of European ancestry, indicating a lack of diversity in human genetics. Disparate representation may result in disparities that impede the equitable adoption of personalized medicine and may also limit our knowledge of illness etiology. Even though Parkinson’s disease (PD) is a global affliction, the AfrAbia population remains understudied. We conducted a dynamic and longitudinal bibliometric analysis to investigate existing studies on Parkinson’s disease genetics in the AfrAbia area and identify data gaps and possible new research avenues. All PD papers concentrating on PD genetics were found using the search terms “Parkinson’s Disease”, “Genetics”, and “Africa” in the PubMed/MEDLINE database. Only English publications published between 1992 and 2023 were chosen using filters. Original English-language research publications disclosing genetic results on Parkinson’s disease in non-European Africans were examined for inclusion. Two sets of independent reviewers discovered and extracted pertinent data. The bibliometric study was carried out using the R software packages Bibliometrix and Biblioshiny. The narrowed search yielded 43 publications, all published between 2006 and 2022. Yet, after applying filters and considering the inclusion requirements, the search results comprise just 16 original articles out of 43 articles. There were 27 articles eliminated. This study puts emphasis on the critical need for more diverse participant demographics in Parkinson’s disease investigations. AfrAbia-PD-Genetic Consortium (AAPDGC) is GP2 initiative that helps to represent AfrAbia PD genetics

A child with fits: a case report for PBL

This is a case report for a child with seizures. It is presented as a PBL for teaching purposes in Medical School for Undergraduate Medical Student

Editorial: biomarkers in neurology

Neurological disorders constitute a major health and socioeconomic problem. They represent the second cause of death and the leading cause of disability throughout the world. Despite the implementation of strategies and intervention programs to reduce the burden, over the past 25 years, the incidence, prevalence, mortality, and disability rates of neurological disorders are rising globally, mainly due to population aging and growth (1). This has placed heavy pressure on health-care systems pointing out the urgent need to identify new strategies to improve patient outcomes and reduce health costs by enabling more effective drug development and establishing a more personalized medicine approach. Rapid scientific and technical advances have enabled reliable and affordable measurement of novel biomarkers—biological indicators that objectively measure and evaluate physiological or pathophysiological processes or pharmacological responses to a therapeutic intervention (2)—which have been suggested to help assessment and management of patients with neurological disorders beyond current practice standards (3–5). Evidence suggests a potential variety of clinical applications, including enhancing diagnostic and prognostic accuracy, improving the existing decision criteria for early diagnosis and risk stratification, as well as assisting in disease monitoring, and acting as surrogate endpoints in experimental studies and clinical trials (6–10). In addition, biomarkers may reliably capture the different aspects of disease heterogeneity and pathogenesis, helping characterize patients, and thereby informing targeted tailored treatments and predicting response outcomes to interventions (11–18). However, despite large numbers of candidate biomarkers have been proposed and extensively evaluated, very few are currently integrated into routine clinical practice and the quest for novel brain injury markers in still ongoing (19)